BioMarin Pharmaceuticals BMRN Pre-Tax Income
Pre-Tax Income at other companies
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.
The official record: BioMarin Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioMarin Pharmaceuticals's pre-tax income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioMarin Pharmaceuticals's pre-tax income?
- BioMarin Pharmaceuticals (BMRN) reported pre-tax income of $141.2M in Q1 2026.
- How has BioMarin Pharmaceuticals's pre-tax income changed year-over-year?
- BioMarin Pharmaceuticals's pre-tax income decreased by 40.7% year-over-year, from $238.09M to $141.2M.
- What is the long-term trend for BioMarin Pharmaceuticals's pre-tax income?
- Over 3 years (2021 to 2025), BioMarin Pharmaceuticals's pre-tax income has grown at a 89.1% compound annual growth rate (CAGR), from -$75.35M to $509.63M.
- What does pre-tax income mean?
- The profit a company makes before paying income taxes.
- How do you interpret pre-tax income?
- Higher values indicate stronger operational profitability and better management of core business expenses.
- How does pre-tax income compare across companies?
- Standardized across all public companies; essential for comparing operating margins across different tax environments.